24/7 New Patient Hotline +1 (855) 437-2745

Idrasil™ Advantages

Medical Cannabis in general and Idrasil™ specifically, have been identified to be a beneficial treatment reflected through studies and science for numerous medical ailments and conditions. With all the research that is coming out every day, it can be hard to keep up with all the latest information. Below you will find a list of numerous medical conditions and by clicking on the specific ailment you will find more specific information about how Idrasil™ (Medical Cannabis) can help.

AUTOIMMUNE DISEASE

X. Yang, V. L. Hegde, R. Rao, J. Zhang, P. S. Nagarkatti, M. Nagarkatti. Histone modifications are associated with Delta(9)-tetrahydrocannabinol-mediated alterations in antigen-specific T cell responses. Journal of Biological Chemistry. 2014. DOI: 10.1074/jbc.M113.545210

ADD/ADHD

Strohbeck-Kuehner P, Skopp G. Mattern R. Cannabis improves symptoms of ADHD. Case Study, Institute of Legal- and Traffic Medicine, Heidelberg University Medical Centre. 2008.

ALS (Lou Gehrig's Disease)

1. Jacob Kaufman, Kelly Almasy, Ashley Boller, Nabila Dahodwala, Lauren Elman, Mary Kelley, Leo McCluskey. Medical Marijuana Utilization and Perceived Therapeutic Value in Patients with ALS (P3.014).

Neurology. 2015. Online ISSN: 1526-632X

 

2. Carter GT, Abood ME, Aggarwal SK, Weiss MD. Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials. The American Journal of hospice and palliative care. 2010. PMID: 20439484

ALZHEIMER'S

Cao C, Li Y, Liu H, Bai G, Mayl J, Lin X, Sutherland K, Nabar N, Cai J. The potential therapeutic effects of THC on Alzheimer's disease. Journal of Alzheimer's Disease (JAD). 2014. PMID: 25024327

ANOREXIA

Andries A, Frystyk J, Flyvbjerg A, Støving RK. Changes in IGF-I, urinary free cortisol and adipokines during dronabinol therapy in anorexia nervosa: Results from a randomised, controlled trial. Growth Hormone and IGF Research Official Journal of the Growth Hormone Research Society and the International IGF Research Society. 2015. PMID: 26248813

ANXIETY/ DEPRESSION

Walsh Z, Gonzalez R, Crosby K, S Thiessen M, Carroll C, Bonn-Miller MO. Medical cannabis and mental health: A guided systematic review. Clinical Psychology Review. 2017. PMID: 27816801

ARTHRITIS

1. Burston JJ1, Sagar DR, Shao P, Bai M, King E, Brailsford L, Turner JM, Hathway GJ, Bennett AJ, Walsh DA, Kendall DA, Lichtman A, Chapman V. Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint. PLOS One. 2013. PMID: 24282543

2. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary Assessment of the Efficacy, Tolerability and Safety of a Cannabis-Based Medicine (Sativex) in the Treatment of Pain Caused by Rheumatoid Arthritis. Rheumatology. 2005. PMID: 16282192

 

AUTISM

Aran A, Shaare Zedek Medical Center. Cannabinoids for Behavioral Problems in Children With ASD (CBA). Shaare Zedek Medical Center. 2016. NCT02956226

BIPOLAR DISORDERS

1. Braga RJ, Burdick KE, Derosse P, Malhotra AK. Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder. Psychiatry Research. 2012. PMID: 22818174

2. Grinspoon L, Bakalar JB. The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research. Journal of Psychoactive Drugs. 1998. PMID: 9692379

CANCER

1. Schleider LB, Mechoulam R, Lederman V, Hilou M, Lencovsky O, Betzalel O, Shbiro L, Novack V. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. European Journal of Medicine. 2018. PMID: 29482741.

 

2. McAllister SD, Murase R, Christian RT, Lau D, Zielinski AJ, Allison J, Almanza C, Pakdel A, Lee J, Limbad C, Liu Y, Debs RJ, Moore DH, Desprez PY. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Research and Treatment. 2011. PMID: 20859676.

 

3. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management. 2011. PMID: 19896326

 

4. Duran M, Pérez E, Abanades S, Vidal X, Saura C, Majem M, Arriola E, Rabanal M, Pastor A, Farré M, Rams N, Laporte JR, Capellà D. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. British Journal of Clinical Pharmacology. 2010. PMID: 21039759.

 

5. McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Molecular Cancer Therapeutics. 2007. PMID: 18025276

 

6. Cannabis-In-Cachexia-Study-Group1, Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, Ko YD, Schnelle M, Reif M, Cerny T. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. Journal of Clinical Oncology. 2006. PMID:16849753

 

7. Guzmán M. Cannabinoids: potential anticancer agents. Nature Reviews - Cancer. 2003. PMID: 14570037

 

8. Schwartz RH, Voth EA, Sheridan MJ. Marijuana to Prevent Nausea and Vomiting in Cancer Patients: A Survey of Clinical Oncologists.Southern Medical Journal. 1997. PMID: 9042166

 

9. Doblin RE, Kleiman MA. Marijuana as Antiemetic Medicine: A Survey of Oncologists' Experiences and Attitudes. American Journal of Clinical Oncology.1991. PMID: 2045870

 

CROHN'S / COLITIS / IBS

Naftali T1, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clinical Gastroenterology and Hepatology. 2013

DIABETES
ENDOCRINE DISORDERS

Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrine Reviews. 2006. PMID: 16306385

EPILEPSY

Rosenberg EC, Louik J, Conway E, Devinsky O, Friedman D. Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol. Epilepsia. 2017. PMID: 28617940

 

FIBROMYALGIA

Fiz J, Durán M, Capellà D, Carbonell J, Farré M. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PLOS One. 2011. PMID: 21533029

GASTROINTESTINAL DISORDERS

*see: CROHN'S / COLITIS / IBS

GLAUCOMA

1. Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. Journal of Glaucoma. 2006. PMID: 16988594

 

2. Tomida I, Pertwee RG, Azuara-Blanco A. Cannabinoids and glaucoma. British Journal of Ophthalmology. 2004. PMID: 15090428

 

HARM REDUCTION

1. Melamede R. Harm reduction--the cannabis paradox. Harm Reduction Journal. 2005. PMID: 16179090

 

2. Lau N, Sales P, Averill S, Murphy F, Sato SO, Murphy S. A safer alternative: Cannabis substitution as harm reduction. Drug and Alcohol Review. 2015. PMID: 25919477

 

3. Collen M. Prescribing cannabis for harm reduction. Harm Reduction Journal. 2012. PMID: 22208773

HEPATITIS C

Sylvestre DL, Clements BJ, Malibu Y. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. European Journal of Gastroenterology and Hepatology. 2006. PMID: 16957511

HIV/AIDS

1. Ronald J Ellis, Will Toperoff, Florin Vaida, Geoffrey van den Brande, James Gonzales, Ben Gouaux, Heather Bentley, and J Hampton Atkinson. Smoked Medicinal Cannabis for Neuropathic Pain in HIV. Neuropsychopharmacology. 2011. PMID: 18688212

 

2. Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, Foltin RW. Dronabinol and Marijuana in HIV-Positive Marijuana Smokers: Caloric Intake, Mood, and Sleep. Journal of Acquired Immune Deficiency Syndromes. 2007. PMID: 17589370

 

3. Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen KL. Cannabis in Painful HIV-Associated Sensory Neuropathy: A Randomized Placebo-Controlled Trial. Neurology. 2005. PMID: 17296917

 

4. Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A. Cannabis use in HIV for pain and other medical symptoms. Journal of Pain and Symptom Management. 2005. PMID: 158577394.

 

5. Prentiss D, Power R, Balmas G, Tzuang G, Israelski DM. Patterns of Marijuana Use Among Patients with HIV/AIDS Followed in a Public Health Care Setting. Journal of Acquired Immune Deficiency Syndromes. 2004. PMID: 14707790

 

5. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M. Short-term Effects of Cannabinoids in Patients with HIV-1 Infection: A Randomized, Placebo-controlled Clinical Trial. Annals of Internal Medicine. 2003. PMID: 12965981

 

7. Cabral G. Marijuana and Cannabinoids: Effects on Infections, Immunity, and AIDS. Journal of Neurology. 2001. 2:1, pages 3-57.

 

8. Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, Schram K. Controlled Clinical Trial of Cannabidiol in Huntington's Disease. Pharmacology, Biochemistry and Behavior. 1991. PMID: 1839644

 

9. Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, Schram K. Controlled Clinical Trial of Cannabidiol in Huntington's Disease. Pharmacology, Biochemistry and Behavior. 1991. PMID: 1839644

INFLAMMATORY BOWEL DISEASE (IBD/CROHN'S DISEASE)

1. Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN. Cannabis Use Provides Symptom Relief in Patients with Inflammatory Bowel Disease but Is Associated with Worse Disease Prognosis in Patients with Crohn's Disease. Inflammatory Bowel Diseases. 2014. PMID: 24407485


2. Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis Induces a Clinical Response in Patients with Crohn's Disease: A Prospective Placebo-Controlled Study. Clinical Gastroenterology and Hepatology. 2013. PMID: 23648372

HYPERTENSION/CARDIO

Crawford WJ, Merritt JC. Effects of tetrahydrocannabinol on arterial and intraocular hypertension. International Journal of Clinical Pharmacology and Biopharmacology. 1979. PMID: 468444

MIGRAINE HEADACHES
MUSCULAR DYSTROPHY

Giusti GV, Chiarotti M, Passatore M, Gentile V, Fiori A. Muscular dystrophy in mice after chronic subcutaneous treatment with cannabinoids. Forensic Science. 1977. PMID: 903049

PAIN / CHRONIC PAIN

1. New York State Department of Health. New York State Department of Health Announces Opioid Replacement Now a Qualifying Condition for Medical Marijuana. Press Release. 2018

 

2. Minnesota Department of Health, Office of Medical Cannabis. Intractable pain patients in the Minnesota medical cannabis program: Experience of enrollees during the first five months. The MDH Office of Medical Cannabis. 2018.

 

3. Di Liang, Yuhua Bao, Mark Wallace, Igor Grant, Yuyan Shi. Medical Cannabis Legalization and Opioid Prescriptions: Evidence on US Medicaid Enrollees during 1993‐2014. Wiley Online Library. 2018 PMID: 29989239

 

4. Di Liang, Yuhua Bao, Mark Wallace, Igor Grant, Yuyan Shi. Medical Cannabis Legalization and Opioid Prescriptions: Evidence on US Medicaid Enrollees during 1993‐2014. Wiley Online Library. 2018 PMID: 29989239

 

5. Vigil JM, Stith SS, Adams IM, Reeve AP. Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study. PLOS One. 2017. PMID: 29145417

 

6. Webb CW, Webb SM. Therapeutic Benefits of Cannabis: A Patient Survey. Hawaii Journal of Medicine and Public Health. 2014. PMID: 24765558

 

7. Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low Dose Vaporized Cannabis Significantly Improves Neuropathic Pain.  Journal of Pain. 2013. PMID: 23237736

 

8. Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa A, Bennett GJ, Collet JP. Smoked Cannabis for Chronic Neuropathic Pain: A Randomized Controlled Trial. Canadian Medical Association Journal. 2010. PMID: 20805210

 

9. Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, Fishman S. A Randomized, Placebo Controlled Cross-Over Trial of Cannabis Cigarettes in Neuropathic Pain. Journal of Pain. 2008. PMID: 18403272

 

10. Berman JS, Symonds C, Birch R. Efficacy of Two Cannabis Based Medicinal Extracts for Relief of Central Neuropathic Pain from Brachial Plexus Avulsion: Results of a Randomised Controlled Trial.

Pain. 2004. PMID: 15561385

 

11. Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis Use for Chronic Non-Cancer Pain: Results of a Prospective Survey. Pain. 2003. PMID: 12620613

PARKINSON’S

1. Lotan I, Treves TA, Roditi Y, Djaldetti R. Cannabis (Medical Marijuana) Treatment for Motor and Non–Motor Symptoms of Parkinson Disease: An Open-Label Observational Study. Clinical Neuropharmacology. 2014. PMID: 24614667

 

2. Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, Parkin SG, Fox P, Wright D, Hobart J, Zajicek JP. Cannabis For Dyskinesia In Parkinson Disease: A Randomized Double-blind Crossover Study. Neurology. 2004. PMID: 15477546

 

3. Venderová K, Růzicka E, Vorísek V, Visnovský P. Survey on Cannabis Use in Parkinson's Disease. Movement Disorders. 2004. PMID: 15372606

PEDIATRIC EPILEPSY

Bláthnaid McCoy, Laura Wang,  Maria Zak,  Sameer Al‐Mehmadi,  Nadia Kabir,  Kenda Alhadid, Kyla McDonald, Grace Zhang, Rohit Sharma,  Robyn Whitney, Katia Sinopoli,  and O. Carter Snead, III Pediatric Epilepsy Study of Dravet's syndrome Published online 2018 Aug 1. doi:  10.1002/acn3.621

PTSD

1. Greer GR, Grob CS, Halberstadt AL. PTSD Symptom Reports of Patients Evaluated for the New Mexico Medical Cannabis Program. Taylor and Francis Online. 2014. PMID: 24830188

 

2. Neumeister A1, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A, Potenza MN, Bailey CR, Lin SF, Najafzadeh S, Ropchan J, Henry S, Corsi-Travali S, Carson RE, Huang Y. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Nature.com. 2013. PMID: 23670490

 

3. Roitman P, Mechoulam R, Cooper-Kazaz R, Shalev A. Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder. SpringerLink. 2014. PMID: 24935052.

PREMENSTRUAL SYNDROME

Pagano E, Orlando P, Finizio S, Rossi A, Buono L, Lannotti FA, Piscitelli F, Izzo AA, Di Marzo V, Borrelli F. Role of the endocannabinoid system in the control of mouse myometrium contractility during the menstrual cycle. Biochemical Pharmacology. 2017. PMID: 27899300

PSYCHOSIS / SCHIZOPHRENIA

Stirling J, Lewis S, Hopkins R, White C. Cannabis Use Prior to First Onset Psychosis Predicts Spared Neurocognition at 10-year Follow-up. Schizophrenia Research. 2004. PMID: 15820332

MULTIPLE SCLEROSIS

1. Flachenecker P, Henze T, Zettl UK. Long-Term Effectiveness and Safety of Nabiximols (Tetrahydrocannabinol/Cannabidiol Oromucosal Spray) in Clinical Practice. European Neurology. 2014. PMID: 24943098

 

2. Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG; MUSEC Research Group. Multiple Sclerosis and Extract of Cannabis: Results of the MUSEC Trial. Journal of Neurology, Neurosurgery & Psychiatry. 2012. PMID: 22791906

 

3. Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, Gouaux B. Smoked Cannabis for Spasticity in Multiple Sclerosis: A Randomized, Placebo-Controlled Trial. Canadian Medical Association Journal. 2012. PMID: 22586334

 

4. Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, Gasperini C, Pozzilli C, Cefaro L, Comi G, Rossi P, Ambler Z, Stelmasiak Z, Erdmann A, Montalban X, Klimek A, Davies P; Sativex Spasticity Study Group. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Enriched-design Study of Nabiximols (Sativex), as Add-on Therapy, in Subjects with Refractory Spasticity Caused by Multiple Sclerosis. European Journal of Neurology. 2011. PMID: 21362108

 

5. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain. Journal of Pain and Symptom Management. 2010. PMID: 19896326

 

6. Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group. Randomized Controlled Trial of Cannabis-Based Medicine in Spasticity Caused by Multiple Sclerosis. European Journal of Neurology. 2007. PMID: 17355549

 

7. Wade DT, Makela P, Robson P, House H, Bateman C. Do Cannabis-based Medicinal Extracts Have General Or Specific Effects on Symptoms in Multiple Sclerosis? A Double-blind, Randomized, Placebo-controlled Study on 160 Patients. Multiple Sclerosis. 2004. PMID: 15327042

 

8. Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M, Reif M. Efficacy of Tetrahydrocannabinol in Patients Refractory to Standard Antiemetic Therapy. Efficacy, Safety and Tolerability of an Orally Administered Cannabis Extract in the Treatment of Spasticity in Patients with Multiple Sclerosis: A Randomized, Double-blind, Placebo-controlled, Crossover Study. Multiple Sclerosis. 2004. PMID: 15327040

 

9. Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ. An Open-Label Pilot Study of Cannabis-based Extracts for Bladder Dysfunction in Advanced Multiple Sclerosis," published in the journal Multiple Sclerosis. Multiple Sclerosis. 2004. PMID: 15327041

 

10. Fox P, Bain PG, Glickman S, Carroll C, Zajicek J. The Effect of Cannabis on Tremor in Patients with Multiple Sclerosis" in the journal Neurology. Neurology. 2004. PMID: 15079008

 

11.  Whittle B, Guy GW, Robson P. Prospects for New Cannabis-Based Prescription Medicines. Journal of Cannabis Therapeutics, 2001. Volume 1 2001, Issue 3-4 pages 183-205

 

12. Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The Perceived Effects of Smoked Cannabis on Patients with Multiple Sclerosis. European Neurology. 1997. PMID: 9252798

 

NEUROPATHY

Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. Journal of Pain. 2013. PMID: 23237736

NAUSEA / VOMITING

Söderpalm AH, Schuster A, de Wit H. Antiemetic Efficacy of Smoked Marijuana: Subjective and Behavioral Effects on Nausea Induced by Syrup of Ipecac. 2001. Pharmacology, Biochemistry and Behavior. PMID: 11509190

SLEEP DISORDERS

Ramar K, Rosen IM, Kirsch DB, Chervin RD, Carden KA, Aurora RN, Kristo DA, Malhotra RK, Martin JL, Olson EJ, Rosen CL, Rowley JA; American Academy of Sleep Medicine Board of Directors. Medical Cannabis and the Treatment of Obstructive Sleep Apnea: An American Academy of Sleep Medicine Position Statement. Journal of Clinical Sleep Medicine. 2018. PMID: 29609727

TOURETTE’S SYNDROME

1. Müller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, Emrich HM. Delta 9-Tetrahydrocannabinol (THC) Is Effective in the Treatment of Tics in Tourette Syndrome: A 6-Week Randomized Trial. Journal of Clinical Psychiatry. 2003. PMID: 12716250

 

2. Müller-Vahl KR, Kolbe H, Schneider U, Emrich HM. Cannabinoids: Possible Role in Patho-physiology and Therapy of Gilles De La Tourette Syndrome. Acta Psychiatrica Scandinavica. 1998. PMID: 9879795

Our mission is to provide safe access to Idrasil™, a patent pending advancement in standardization and administering natural cannabinoids in a pill, for the injured, sick and dying. Idrasil™ is a holistic alternative to addictive opiates and life threatening narcotics without euphoria.

Idrasilrx

Idrasil™ Newsletter

Subscribe to our Newsletter right now to be updated. We promise not to spam!